This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignees: Enliven Therapeutics, Inc., Enliven, Inc.. Active years: 2023-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023-2026
Title: Qiang Su: Innovator in Cancer Treatment
Introduction
Qiang Su is a prominent inventor based in Beijing, China. He has made significant contributions to the field of cancer treatment through his innovative research and development of pharmaceutical compounds.
Latest Patents
Qiang Su holds a patent for "Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2." This patent focuses on compounds and compositions that inhibit ErbB2, including its mutant forms, particularly those with an Exon 20 mutation. The methods outlined in the patent detail the preparation of these compounds and their application in treating various cancers, such as lung, glioma, skin, head and neck, salivary gland, breast, esophageal, liver, stomach, uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder, and prostate cancer.
Career Highlights
Qiang Su is currently employed at Enliven Therapeutics, Inc., where he continues to advance his research in cancer therapeutics. His work is characterized by a commitment to developing effective treatments for challenging cancer types.
Collaborations
Qiang Su collaborates with various professionals in the field, including his coworker Samuel Kintz. Their combined expertise contributes to the innovative projects at Enliven Therapeutics.
Conclusion
Qiang Su's contributions to cancer treatment through his patented inventions highlight his role as a key innovator in the pharmaceutical industry. His work continues to pave the way for advancements in cancer therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile